Active Biotech has Selected a New Candidate Drug for the Treatment of Lupus.Business Editors Active Biotech has selected a Candidate Drug, ABR-215757, within the SLE SLE systemic lupus erythematosus. SLE abbr. systemic lupus erythematosus Systemic lupus erythematosus (SLE) project for further development into clinical phase. The Candidate Drug ABR-215757 is developed for the treatment of SLE (Systemic Lupus Erythematosus Systemic Lupus Erythematosus Definition Systemic lupus erythematosus (also called lupus or SLE) is a disease where a person's immune system attacks and injures the body's own organs and tissues. Almost every system of the body can be affected by SLE. ), which is an autoimmune disease with very few available treatments today. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID NSAID: see nonsteroidal anti-inflammatory drug. (nonsteroidal anti-inflammatory drugs Nonsteroidal Anti-Inflammatory Drugs Definition Nonsteroidal anti-inflammatory drugs are medicines that relieve pain, swelling, stiffness, and inflammation. ), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide cyclophosphamide /cy·clo·phos·pha·mide/ (-fos´fah-mid) a cytotoxic alkylating agent of the nitrogen mustard group; used as an antineoplastic, as an immunosuppressant to prevent transplant rejection, and to treat some diseases . The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses. No new product has been registered for the treatment of this disease since more than forty years. Active Biotech's Candidate Drug ABR-215757 has shown good effect in pre-clinical models for autoimmune diseases, among them SLE, and shows a favorable toxicological profile. According to plan the company estimates that this product will enter clinical development in 2003. The company regards the Intellectual Property rights as very strong for this project, since ABR-215757 is included in the extensive patent portfolio covering the competence platform Q. Other projects based on this competence are: SAIK-MS that currently is in Phase II clinical development for the treatment of multiple sclerosis, the prostate cancer project TASQ TASQ Transparent Auto-Switch Quality (Quitum Technologies) TASQ Tactical Airlift Squadron which is planned to enter Phase I during the spring 2003, and the pre-clinical discovery project IMO-A. SLE- Systemic Lupus Erythematosus - is a connective tissue disease connective tissue disease Autoimmune disease, collagen-vascular disease Any of the diseases affecting connective tissues, with an autoimmune component, and immunologic/inflammatory defects Clinical Arthritis, connective tissue defects, endocarditis, myositis, that causes inflammation and injuries anywhere in the body. The progression and symptoms associated with this disease varies largely, depending on which organs that are involved in the disease. Approximately 1 out of 20 000 individuals is affected and it is most common among young women. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion